Greenland Mines Advances Critical Minerals Strategy with Q4 Biotech Spin-Off and Sarfartoq Acquisition

Greenland Mines is spinning off its biotech division in Q4 2026 to focus on rare earths, following the completion of its Sarfartoq acquisition and a positive economic assessment.

Miami Metrowire Staff
Business
Greenland Mines Advances Critical Minerals Strategy with Q4 Biotech Spin-Off and Sarfartoq Acquisition

Greenland Mines (NASDAQ: GRML) announced a series of corporate milestones as it transitions into a focused rare earths and critical minerals company, including plans to spin off its biotechnology division in the fourth quarter of 2026. Nasdaq has formally approved the company's application relating to its March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements.

The company also completed its acquisition of the Sarfartoq project on Sept. 1 following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. Greenland Mines said planned annual neodymium-praseodymium oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years.

These developments underscore the company's sharpened focus on critical minerals, which are essential for electric vehicle motors, wind turbines, and other clean energy technologies. The Sarfartoq project, located in southwest Greenland, is poised to become a significant supplier of rare earth elements outside China, addressing a critical supply chain gap. The ST1 deposit's robust economic metrics highlight the project's potential to generate substantial returns.

Greenland Mines is also reshaping its board, with Riad El-Dada and Dr. Shalom Hirschman stepping down and capital markets veteran Jason Hawkins joining as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project. The board changes signal a strategic shift toward maximizing value from its mining assets.

The spin-off of the biotech division will allow Greenland Mines to unlock value from its Klotho subsidiary, which is developing KLTO-202 for ALS, while focusing management attention on its mining operations. This separation is expected to streamline operations and provide clearer investment propositions for shareholders.

The company's vision of a North Atlantic Critical Metals Corridor linking Greenland resources with allied downstream jurisdictions and industrial infrastructure positions it strategically in the global race for supply chain security. With the Sarfartoq acquisition complete, Greenland Mines is well-positioned to capitalize on the growing demand for rare earths, which are vital for national security and economic growth in the United States and other allied nations.

For a detailed breakdown of the announcement, the full press release is available at this link. For the latest news and updates on Greenland Mines, visit the company's newsroom.

Blockchain Registration

QR Code for Blockchain Registration